## Hepatitis B (Hep B) Vaccine Administration Considerations for Students in Grades 7 to 12

The following table outlines the Hep B vaccine series based on the student's age, Hep B immunization status, and recommended dosing interval:

Student's Age & Hep B Immunization Status	Dose One	Dose Two	Dose Three
	11-15 years of age		
Students who are starting and completing a Hep B vaccine series between 11 and 15 years of age		Adult formulation*	
Two-dose series	Adult formulation*	Administer six months after the first dose to complete the two-dose series.	Dose <u>not</u> required
Students who started a Hep B vaccine series between 11 and 15 years of age and are completing the series at 16 years of age or older  • Three-dose series	11-15 years of age	≥ 16 years of age until end of Grade 12	
		Pediatric formulation**	Pediatric formulation**
	✓ Dose already received	Administer one month (minimum 28 days) after the first dose.	Administer five months after the second dose to complete the three-dose series.
Students who are starting and completing a Hep B vaccine series at 16 years of age or older  • Three-dose series	≥ 16 years of age until end of Grade 12		
	Pediatric formulation**	Pediatric formulation**	Pediatric formulation**
			Adada talatan Caraman dha a Gan
Three-dose series	Pediatric formulation**	Administer one month (minimum 28 days) after the first dose.	Administer five months after the second dose to complete the three-dose series.

<sup>\*</sup>Adult formulation = 20mcg Engerix®-B or 10mcg Recombivax HB®

Interruption of a Hep B vaccine series does <u>not</u> require restarting the series, regardless of the length of time that has elapsed since the last dose. When reporting Hep B vaccine administration to <u>York Region Public Health</u>, it is important to specify if an **adult <u>or</u> pediatric formulation** was administered.



1-877-464-9675 ext. 74033 york.ca/vaccineinventory



<sup>\*\*</sup>Pediatric formulation = 10mcg Engerix®-B or 5mcg Recombivax HB®

## Human Papillomavirus 9-Valent (HPV-9) Vaccine Administration Considerations for Students in Grades 7 to 12

The following table outlines the HPV-9 vaccine series based on the student's age, HPV-9 immunization status, and recommended dosing interval:

Student's Age & HPV-9 Immunization Status	Dose One	Dose Two	Dose Three
Ottodanta volta ana atantin a thain LIDV O casaina assisa	11-14 years of age	Until end of Grade 12	
Students who are starting their HPV-9 vaccine series between 11 and 14 years of age  • Two-dose series	✓	Administer six months after the first dose to complete the two-dose series.	Dose <u>not</u> required
	≥ 15 years of age	Until end of Grade 12	
Students who are starting their HPV-9 vaccine series at 15 years of age or older  • Three-dose series	✓	Administer two months after the first dose.	Administer four months after the second dose to complete the three-dose series.

Interruption of an HPV-9 vaccine series does not require restarting the series, regardless of the length of time that has elapsed since the last dose.

## Meningococcal Conjugate A, C, Y, W-135 (Men-C-ACYW-135) Vaccine Administration Considerations for Students in Grades 7 to 12

Men-C-ACYW-135 Eligibility	Considerations
Students in Grades 7 to 12 <u>and</u> individuals born in or after 1997 regardless of previously receiving the vaccine during	Men-C-ACYW-135 vaccine is required for students attending school in Ontario as outlined in the <a href="Immunization of School Pupils Act (ISPA)">Immunization of School Pupils Act (ISPA)</a> .
infancy or childhood	Individuals remain eligible for the vaccine beyond graduation until the dose is received.
One dose	As per the <u>Canadian Immunization Guide</u> , individuals 12 to 24 years of age are recommended to receive a dose even if they have previously been vaccinated as an infant or toddler.

York Region Public Health

1-877-464-9675 ext. 74033 york.ca/vaccineinventory

